dxd

Dxd (OQM5SD32BQ) is a potent DNA topoisomerase I inhibitor (IC50= 0.31 μM). Dxd was used as a conjugate drug for HER2-targeted ADCs.

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Raludotatug deruxtecan (DS-6000) is an ADC compound targeting CDH6 with anti-cancer activity, used in the study of ovarian cancer.

Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).

C-lock-GGFG-DXd is a thiol-reactive drug linker. GGFG is an enzyme-degradable peptide. After entering the lesion site, it can release the payload DXd and exert its function. C-lock-GGFG-DXd is commonly used in the synthesis of antibody-drug conjugates (ADCs).

C-lock-G5-DXd is a Drug-linker. DXd is an effective inhibitor of DNA topoisomerase I, and is often used in the synthesis of ADC compounds.

Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan. It serves as a linker-toxin structural unit in an antibody-drug conjugate (ADC) for attaching an antibody Cys residue to a cytotoxic drug. Cys-MC-GGFG-Dxd is applicable in cancer research.

Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate for antibody-drug conjugates (ADCs), incorporating an ADC linker and the DNA topoisomerase I inhibitor DXd [1].

DBCO-PEG4-GGFG-Dxd is an ADC linker-payload intermediate used for synthesizing antibody-drug conjugates. This product consists of the DNA topoisomerase I inhibitor Dxd (Deruxtecan) conjugated to a cleavable GGFG tetrapeptide-based linker. The terminal DBCO group functions as a click chemistry handle, enabling strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules for the efficient construction of tumor-targeted ADCs.

DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a derivative of Camptothecin, serves as a linker-payload for protein-agent conjugates [1]. It is utilized as a payload in the antibody-coupling drug ADC (DS-8201a). Additionally, this compound functions as a click chemistry reagent due to its DBCO group, facilitating strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-group-containing molecules.

Val-Cit-PAB-DEA-Dxd (compound 81) serves as a Drug-Linker Conjugate for Antibody-Drug Conjugates (ADCs), comprising a linker coupled with the cytotoxic agent Dxd, a DNA topoisomerase I inhibitor. This compound is utilized in the synthesis of ADCs [1].

Fmoc-GGFG-DXd is a component of antibody-drug conjugates (ADC) known as the drug-linker conjugate for ADC. It comprises a degradable ADC linker, Fmoc-GGFG, and a DNA topoisomerase I inhibitor, DXd.

Dxd-d5, a deuterated derivative of Dxd, acts as a potent DNAtopoisomerase I inhibitor with an IC50 value of 0.31 μM. It serves as the effective payload for the antibody-drug conjugate (ADC) targeting HER2, known as DS-8201a.

Compound 13-7 (Amino-PEG4-GGFG-Dxd) serves as a drug-linker conjugate for antibody-drug conjugates (ADC) and is applicable in the synthesis of ADCs .

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.

Deruxtecan analog 2 (monoTFA), a homolog of Deruxtecan, consists of the antibody-drug conjugate (ADC) toxin derivative DX-8951 (Dxd) connected through an ADC linker [1].

Human IgG1 (K214R) kappa-Deruxtecan, ADC Control (DAR 4) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 4. It can be used as a control in ADC.

Human IgG1 kappa-Deruxtecan, ADC Control (DAR 4) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 4. It can be used as a control in ADC.

Human IgG1 (K214R) kappa-Deruxtecan, ADC Control (DAR 8) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 8. It can be used as a control in ADC.

Human IgG1 (LALAPG) kappa-Deruxtecan, ADC Control is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with Fc LALAPG modification. It can be used as a control in ADC.

Human IgG1 kappa-Deruxtecan, ADC Control (DAR 8) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 8. It can be used as a control in ADC.

LE01 is a component of the antibody-drug conjugate (ADC) known as a drug-linker conjugate for ADC. It comprises an ADC linker and the DNA topoisomerase I inhibitor DXd. LE01 is used in the synthesis of the HER2-targeting antibody-drug conjugate named HER2-LE01.